(Q43682745)

English

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

P K Schädlich

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

J G Brecht

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

M Brunetti

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

E Pagano

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

B Rangoonwala

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

E Huppertz

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

5 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

497-512

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Understanding the nature of renal disease progression

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Annual Report of the German Renal Registry 1998. QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Renal protective effect of enalapril in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

The future of pharmacoeconomics: a commentary

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Renal protection and antihypertensive drugs: current status

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200119050-00005

21 January 2018

Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dialysis therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of benazepril in chronic renal insufficiency.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension as cause of end-stage renal disease: lessons from international registries.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure and end-stage renal disease in men

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The economic costs of NIDDM

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of progression of nephropathy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of ACE inhibitor treatment of nephropathy in patients with insulin-dependent diabetes mellitus in Italy

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report on management of renal failure in Europe, XXIV, 1993

1 reference

https://pubmed.ncbi.nlm.nih.gov/11465309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00019053-200119050-00005

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43682745&oldid=2206201365"